The company says a recent coverage decision by Medicare has forced it to end an observational trial of the Alzheimer’s drug after enrolling just 29 participants.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,